Trial Profile

A PK bridging study of GTX-102 for Ataxia telangiectasia

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 10 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Betamethasone (Primary)
Indications Ataxia telangiectasia
Focus Pharmacokinetics; Therapeutic Use
Sponsors Acasti Pharma; Grace Therapeutics

Most Recent Events

25 Oct 2024 According to an Acasti Pharma media release, company name Acasti Pharma changed to Grace Therapeutics, Inc.
22 Dec 2022 According to an Acasti Pharma media release, the company expects to report topline results of the study before the end of December 2022.
21 Jun 2022 According to a Acasti Pharma media release, results are expected before the end of calendar 2022 and if the study meets the primary endpoint, an NDA filing under Section 505(b)(2) would follow.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com